Results 221 to 230 of about 54,087 (251)
Some of the next articles are maybe not open access.
Antifibrinolytic agents in cardiac surgery: Current controversies
Seminars in Thoracic and Cardiovascular Surgery, 2005Antifibrinolytic agents play a prominent role in adult cardiac surgery. This article is a review of the modern published experience of antifibrinolytic agent use in adult cardiac surgery. The use of tranexamic acid, epsilon-aminocaproic acid, and aprotinin is examined during primary cardiac surgery, deep hypothermic circulatory arrest, reoperative ...
John D. Puskas +2 more
openaire +2 more sources
The Use of Antifibrinolytic Agents in Spine Surgery
The Journal of Bone and Joint Surgery-American Volume, 2008Antifibrinolytic agents have been shown to decrease the blood loss associated with major orthopaedic surgical procedures. Spine surgery, particularly procedures performed for deformity correction and procedures involving long arthrodesis constructs, can be associated with a large amount of blood loss requiring blood transfusions.
Andrew Levin +3 more
openaire +3 more sources
Antifibrinolytic Agents for Hemoptysis Management in Adults With Cystic Fibrosis
Chest, 2019Hemoptysis is a major cause of morbidity and mortality in patients with cystic fibrosis (CF). Antifibrinolytic agents have shown efficacy in a broad range of bleeding disorders and conditions.The goal of this study was to examine the use of antifibrinolytic agents in managing hemoptysis in CF. We developed a clinical treatment pathway for inpatient and
Simona Rits +13 more
openaire +3 more sources
Fibrinolysis, Antifibrinolytic Agents, and Perioperative Considerations
2021Fibrinolysis is an integral component of hemostasis that acts to regulate fibrin formation. Its actions are counterbalanced by the coagulation process, maintaining against excess clot formation or hemorrhage. Excessive release of plasmin through surgery or other means can result in a pathophysiological state characterized by bleeding, inflammation, and
openaire +2 more sources
Antifibrinolytic Agents in the Management of Traumatic Hyphema
Archives of Ophthalmology, 1983Clinical confusion often exists when therapeutic alternatives for a particular disease have not been rigorously compared. This problem is typical of the series of clinical decisions required in the management of traumatic hyphema and its complications. For example, should the patient (1) be admitted to the hospital, (2) undergo bilateral or unilateral ...
openaire +3 more sources
Antifibrinolytic Agents and Desmopressin as Hemostatic Agents in Cardiac Surgery
The Annals of Pharmacotherapy, 2001OBJECTIVE: To review the use of systemic hemostatic medications for reducing bleeding and transfusion requirements with cardiac surgery. DATA SOURCES: Articles were obtained through computerized searches involving MEDLINE (from 1966 to September 2000).
openaire +3 more sources
ChemInform Abstract: Tranexamic Acid: A Proven Antifibrinolytic Agent
ChemInform, 2010AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
Naga Jahnavi Vemu +2 more
openaire +2 more sources
The Use of Antifibrinolytic Agents in Total Hip Arthroplasty
The Journal of Arthroplasty, 2006Total hip arthroplasty is associated with significant blood loss that often requires allogenic blood transfusions. Tranexamic acid and aprotinin have been shown to reduce blood loss and transfusions in clinical trials with variable results. This meta-analysis evaluates whether tranexamic acid and aprotinin significantly reduces blood loss and ...
Alexander D Rosenstein, J. Brian Gill
openaire +3 more sources
The use of haemostatic drugs in haemophilia: desmopressin and antifibrinolytic agents
Haemophilia, 2002Summary. Over the last 4 decades, there have been very significant advances in the treatment of haemophilia. Plasma products first became available in the 1960s, beginning with cryoprecipitate and then intermediate‐purity plasma concentrates, for the treatment of haemophilia A and B. The disasters of viral infections amongst people with haemophilia in
A. Villar +3 more
openaire +3 more sources
Effects of antifibrinolytic agents on the life span of fibrin sealant
Journal of Surgical Research, 1992Fibrin sealant, a biologic glue consisting of fibrinogen and thrombin, has been used in a variety of surgical procedures. The usefulness of fibrin sealant may be prolonged by the addition of antifibrinolytic agents. This study compared the efficacy of transexamic acid (30 mg/ml), epsilon-aminocaproic acid (25 mg/ml), and aprotinin (3000 KIU/ml) to ...
Thomas L. Matthew +6 more
openaire +3 more sources